Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to control partial, generalized tonic‑clonic and myoclonic seizures in patients with epilepsy and is part of standard epilepsy management protocols.

GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. Our distribution network ensures reliable delivery, regulatory compliance and product integrity across multiple regions. We work closely with local authorities to maintain quality standards and support patient care initiatives.

Levetiracetam is an antiepileptic drug used to manage several seizure types within the epilepsy disease spectrum. - Partial seizures: reduces frequency and severity of focal onset seizures. - Generalized tonic‑clonic seizures: helps prevent convulsive episodes in patients with generalized epilepsy. - Myoclonic seizures: controls rapid, involuntary muscle jerks associated with juvenile myoclonic epilepsy.

Levetiracetam may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness or lack of energy. - Somnolence: increased sleepiness during the day. - Irritability: mood changes including agitation. - Headache: mild to moderate cranial pain. - Nausea: upset stomach or urge to vomit.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: serious skin blistering and detachment. - Blood dyscrasias: abnormal blood cell counts such as leukopenia. - Suicidal thoughts: emergence of depression or suicidal ideation. - Severe skin rash: including toxic epidermal necrolysis. - Depression: new or worsening depressive symptoms.

Before prescribing Levetiracetam, clinicians should evaluate several safety considerations to minimize risk. - Renal impairment: adjust dose based on creatinine clearance. - Hepatic impairment: monitor liver function tests regularly. - Pregnancy: use only if potential benefit justifies potential risk; data are limited. - Concomitant CNS depressants: monitor for additive sedation. - Mood changes: observe for new or worsening depression or suicidal thoughts. - Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Levetiracetam can interact with other medicines, influencing its plasma concentration or therapeutic effect.

Major Interactions (Avoid): - Carbamazepine: enzyme induction reduces levetiracetam levels. - Phenobarbital: increases metabolism leading to lower efficacy. - Phenytoin: strong enzyme inducer that may diminish seizure control.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam concentrations; monitor for toxicity. - Antidepressants (e.g., SSRIs): potential for heightened mood alterations. - Alcohol: combined use can enhance central nervous system depression.